Skip to main content
TipRanks
Go Ultimate75% OFF

Intercure (INCR) AI Stock Analysis

101 Followers
INCR

Intercure

(NASDAQ:INCR)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue RecoveryThe return to revenue growth indicates improved demand or execution after two years of contraction. If maintained, renewed top-line momentum can broaden the company’s operating base, support fixed-cost absorption, and provide a foundation for rebuilding profitability over the next several quarters.
Negative Factors
Persistent LossesContinued net losses show that the recent revenue recovery has not yet translated into durable earnings power. A negative net margin limits internally generated capital, makes results more sensitive to execution and cost control, and leaves the business needing sustained improvement before profitability can be considered established.

Intercure (INCR) vs. SPDR S&P 500 ETF (SPY)

-50%-40%-30%-20%-10%0%10%20%30%INCR-46.76%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$146.46M
Dividend Yield
―
Average Volume (3M)
25.25K
Price to Earnings (P/E)
-3.5
Beta (1Y)
0.78
Revenue Growth
―
EPS Growth
―
Country
US
Employees
285
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Intercure Business Overview & Revenue Model

Company Description

InterCure Ltd., alongside its affiliated companies, is actively involved in the medical cannabis industry, operating both domestically in Israel and internationally. Their activities encompass the entire spectrum from research and cultivation to prod...

Intercure Risk Analysis

Intercure disclosed 68 risk factors in its most recent earnings report. Intercure reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Intercure Peers Comparison

Overall Rating

Financial Indicators

INCR against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%INCRIL:TGTRIL:CNZN.MIL:SEMGDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
INCR and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
INCRIntercure3.49-3.02-46.40%
IL:TGTRTogether Pharma Ltd.180.80-163.50-47.49%
IL:CNZN.MCanzon-M90.001.902.16%
IL:SEMGSeach Medical Group Ltd.281.4038.6615.93%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.